The general partner of the 2023 GMP Conference is Binnopharm Group, a leading Russian pharmaceutical company centrally managing manufacturing sites in different regions of the country.

Binnopharm Group produces a wide range of high-quality prescription and over-the-counter medicines: 450+ marketing authorizations, 200+ pharmacological classes, 370+ mln packs annually.

The Binnopharm Group production complex includes five manufacturing sites: Alium JSC (Obolensk village, Moscow region), Binnopharm JSC (Zelenograd and Krasnogorsk), Sintez PJSC (Kurgan), Biocom JSC (Stavropol). The facilities manufacture all existing dosage forms, i.e. solids, liquids, semi-solids and gases.

Every year, Binnopharm Group invests over 2 billion rubles in the modernization of production facilities.

The company’s medicines are manufactured using state-of-the-art equipment in accordance with GMP standards. Having its own production of active pharmaceutical ingredients allows for manufacturing of up to 26% full-cycle products.

In 2023, Binnopharm Group launched one of the most innovative R&D centers in Russia, which includes chemical and biotech laboratories for the development of medicines. This R&D center combined the competencies of the three laboratories located at the company’s manufacturing sites.

By 2025, Binnopharm Group is planning to introduce more than 100 new medicines to the market.

Sintez facility in Kurgan

It manufactures active pharmaceutical ingredients and medicines in 18 dosage forms, including natural and semi-synthetic antibiotics, as full-cycle. The facility is the largest manufacturer of antibiotics in Russia and one of the city-forming enterprises of Kurgan.

• Binnopharm facility in Zelenograd

It manufactures original combination medicines, biosimilars of completely original and biotech medicines of various therapeutic groups, such as pulmonology, neurology, cardiology, gastroenterology and endocrinology. In 2020, the Binnopharm facility became the world’s first site for the manufacture of the COVID-19 vaccine – Gam-COVID-Vac (Sputnik V).

• Binnopharm facility in Krasnogorsk

It manufactures infusion solutions. The design capacity allows for manufacturing 30 mln plastic bottles per year. The facility is designed and built in full compliance with GMP standards.

• Alium facility in Obolensk village of Moscow region

It manufactures prescription and over-the-counter medicines of various therapeutic groups, such as pulmonology, neurology, cardiology, gastroenterology, infectious and cold-related diseases, phlebology, urology, antibiotics and antiseptics, painkillers. The facility is also designed in full compliance with GMP standards.

• Biocom facility is Stavropol

It manufactures small-scale and medium-scale batches of solid dosage forms. These are medicines for the treatment of diseases of the nervous system, gastrointestinal tract, tuberculosis, prevention of influenza and acute respiratory viral infection. In 2021, the facility was completely rebuilt to improve.

The quality of Binnopharm Group’s medicines is secured by QC laboratories employing more than 350 people. The laboratory complex equipped with state-of-the-art equipment also includes a unique pharmacological laboratory and a vivarium.

At the GMP Conference, representatives of Binnopharm Group will share best practices in continuous improvement of the quality system and implementation of the latest EAEU GMP requirements.